The Washington Manual of Cardio-Oncology

Title of the Book

▶ Click Image or Title to the Page on the Site

The Washington Manual of Cardio-Oncology

Product details

 

도서명: The Washington Manual of Cardio-Oncology

저 자: Daniel J. Lenihan

출판사: Lippincott W&W

ISBN : 9781975180447

출판일: 2022.03

판 형: Softcover

판 수: 1/e

면 수: 380 page

 

Description

 

Written by experts in cardiovascular disease, hematology, and oncology, The Washington Manual® of Cardio-Oncology: A Practical Guide for Improved Cancer Survivorship is a clinically relevant, easy-to-use primer on the detection, management, and improved cardiovascular-based patient outcomes in adults undergoing treatment for cancer or who have previously survived cancer therapy. Edited by Drs. Daniel J. Lenihan, Joshua D. Mitchell, and Kathleen W. Zhang, this concise yet comprehensive manual provides high-yield information that reflects today’s advances in risk stratification, early diagnosis, and treatment of cardiovascular disease—all in an easy-access, concisely bulleted format for on-the-go reference.

Discusses the multitude of complex adverse effects of chemotherapy, targeted therapy, immunotherapy, and radiation therapy to help optimize quality of life and prolong survival in this vulnerable patient population.

Includes chapters on how cancer therapy affects the myocardium, valves, pericardium and cardiac electrical system including handy reference tables on typical side effects of commonly used cancer therapies.

Provides practical guidance in an easy-to-follow format that covers definition, associated drugs/therapies, epidemiology, diagnosis (history, physical exam, and diagnostic testing), treatment, and outcome/prognosis.

Covers the role of non-invasive imaging modalities in the diagnosis and screening for cardiovascular disease including echocardiography, MRI, and nuclear imaging.

Addresses frequently encountered clinical scenarios such as preoperative or pre-high-risk treatment evaluation with up-to-date expert consensus recommendations.

Details emerging treatments and optimal use of non-invasive imaging in cardiac amyloidosis.

Features easy-to-use flow-charts and tables that aid in the differentiation of cardiac masses.

The Washington Manual® is a registered mark belonging to Washington University in St. Louis to which international legal protection applies. The mark is used in this publication by Wolters Kluwer Health under license from Washington University.

 

Enrich Your eBook Reading Experience

Read directly on your preferred device(s),such as computer, tablet, or smartphone.

Easily convert to audiobook,powering your content with natural language text-to-speech.

 

Table of Contents

 

1 A Practical Approach to the Evaluation of a Cardio-Oncology Patient

GENERAL PRINCIPLES

Definition

Classification

Epidemiology

Etiology

Risk Factors

History

PATHOPHYSIOLOGY AND SPECIFIC TOXICITIES

Alkylating Agents

Androgen Deprivation Therapy, Antiandrogens, Androgen Receptor Blockers

Anthracyclines

Checkpoint Inhibitors (Programmed Death 1/Programmed Cell Death Ligand 1 and Cytotoxic T-lymphocyte-Associated Antigen 4 Inhibitors)

Chimeric Antigen Receptor T-Cell Therapy

Fluoropyrimidine

Human Epidermal Growth Factor Receptor 2 Targeted Therapies

Immunomodulatory Agents

PI3K/AKT/mTOR Inhibitor

Proteasome Inhibitors

Tyrosine Kinase Inhibitors

Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

Select Other Medications and Cardiovascular Adverse Effects

Radiation (Chest/Mediastinal)

PREVENTION

ABCDEs of Prevention

Coronary Vasospasm

Left Ventricular Dysfunction

Thrombosis

Torsades de Pointes

DIAGNOSIS OF CARDIOVASCULAR ADVERSE EVENTS DURING CANCER THERAPY

Clinical Presentation

Diagnostic Criteria

TREATMENT OF SPECIFIC CARDIAC DISEASES

Medications

Other Nonpharmacologic Therapies (Lifestyle)

SPECIAL CONSIDERATIONS/PULLING IT ALL TOGETHER

REFERRAL

PATIENT EDUCATION

MONITORING/FOLLOW-UP

OUTCOME/PROGNOSIS

REFERENCES

2 Cardiac Dysfunction: Traditional Chemotherapy, Human Epidermal Growth Factor Receptor 2–Based Therapy, and Radiation

GENERAL PRINCIPLES

DEFINITION OF CARDIAC DYSFUNCTION

SPECIFIC DRUGS AND THERAPIES

Anthracyclines

Human Epidermal Growth Factor Receptor 2 Inhibitors

Cyclophosphamide

Radiation

EPIDEMIOLOGY/RISK FACTORS FOR CARDIAC DYSFUNCTION

Anthracyclines

Human Epidermal Growth Factor Receptor 2 Inhibitors

Cyclophosphamide

Radiation

CLINICAL PRESENTATION OF CARDIAC DYSFUNCTION

History

Physical Examination

Diagnostic Testing

TREATMENT OF CARDIAC DYSFUNCTION

OUTCOMES/PROGNOSIS

Anthracyclines

Human Epidermal Growth Factor Receptor 2 Inhibitors

Cyclophosphamide

Radiation Therapy

PREVENTION OF CARDIAC DYSFUNCTION

SURVEILLANCE STRATEGIES FOR CARDIAC DYSFUNCTION

Cardiac Biomarkers

Transthoracic Echocardiography

Cardiac Magnetic Resonance Imaging

Multigated Acquisition Angiogram

REFERENCES

3 Cardiac Dysfunction: Small-Molecule Kinase Inhibitors, Immune-Based Therapies, and Proteasome Inhibitors

SMALL-MOLECULE KINASE INHIBITORS

DEFINITION

ASSOCIATED DRUGS/THERAPIES

EPIDEMIOLOGY

Primary Uses

CARDIOTOXICITY

MONITORING

VASCULAR ENDOTHELIAL GROWTH FACTOR SIGNALING PATHWAY INHIBITORS

DEFINITION

ASSOCIATED DRUGS/THERAPIES

EPIDEMIOLOGY

CARDIOTOXICITY

MONITORING

IMMUNE CHECKPOINT INHIBITORS

DEFINITION

ASSOCIATED DRUGS/THERAPIES

EPIDEMIOLOGY

CARDIOTOXICITY

MONITORING

CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

DEFINITION

ASSOCIATED DRUGS/THERAPIES

EPIDEMIOLOGY

CARDIOTOXICITY

MONITORING

BISPECIFIC ANTIBODIES

DEFINITION

ASSOCIATED DRUGS/THERAPIES

EPIDEMIOLOGY

CARDIOTOXICITY

MONITORING

PROTEASOME INHIBITORS

DEFINITION

ASSOCIATED DRUGS/THERAPIES

EPIDEMIOLOGY

CARDIOTOXICITY

MONITORING

REFERENCES

4 Valvular Heart Disease

GENERAL PRINCIPLES

APPROACH TO VALVULAR HEART DISEASE IN THE CANCER PATIENT

RADIATION-INDUCED VALVULAR HEART DISEASE

GENERAL PRINCIPLES

Epidemiology/Risk Factors

Diagnosis

TREATMENT AND PROGNOSIS

PREVENTION AND SCREENING

CARCINOID HEART DISEASE

GENERAL PRINCIPLES

Epidemiology/Risk Factors

Diagnosis

Laboratory Testing

TREATMENT

OUTCOME/PROGNOSIS

NONBACTERIAL THROMBOTIC ENDOCARDITIS

GENERAL PRINCIPLES

REFERENCES

5 Vascular Disease in Cardio-Oncology

GENERAL PRINCIPLES

SUPERIOR VENA CAVA SYNDROME

GENERAL PRINCIPLES

DIAGNOSIS

Clinical Presentation and Initial Evaluation

MANAGEMENT

CORONARY VASOSPASM AND 5-FLUOROURACIL

GENERAL PRINCIPLES

DIAGNOSIS

Clinical Presentation

MANAGEMENT AND CLINICAL FOLLOW-UP

ACCELERATED ATHEROSCLEROSIS

GENERAL PRINCIPLES

Radiation Therapy

Graft-Versus-Host Disease

Nilotinib and other BCR-ABL Tyrosine Kinase Inhibitors

Immune Checkpoint Inhibitors

CLINICAL PRESENTATION

MANAGEMENT

ACUTE CORONARY SYNDROME

GENERAL PRINCIPLES

Cisplatin and Platinum Compounds

Vascular Endothelial Growth Factor Inhibitors

CLINICAL MANAGEMENT CONSIDERATIONS IN PATIENTS WITH ACUTE CORONARY SYNDROME

REVASCULARIZATION IN ACUTE CORONARY SYNDROME IN THE SETTING OF THROMBOCYTOPENIA

REFERENCES

6 Evaluation for Ischemic Heart Disease in Cardio-Oncology

GENERAL PRINCIPLES

Definition

Classification

Epidemiology

Etiology

Risk Factors

DIAGNOSIS

Clinical History

Laboratory Evaluation

Approach to Diagnostic Testing

Approach to Patients Prior to Noncardiac Surgery

Noninvasive Imaging

INVASIVE IMAGING AND THERAPEUTICS

Invasive Coronary Angiogram

Medical Therapy for Coronary Disease

Percutaneous Coronary Intervention

REFERENCES

7 Pericardial Diseases in Malignancy

GENERAL PRINCIPLES

ANATOMY OF THE PERICARDIUM

ACUTE PERICARDITIS

Definition

Etiology

Diagnosis

Management

Consequences

PERICARDIAL EFFUSIONS

Etiology

Diagnosis

Management

PERICARDIAL TAMPONADE

Pathophysiology

Diagnosis

CONSTRICTIVE PERICARDITIS

Etiology

Diagnosis

Management

Palliation

Complications

REFERENCES

8 Cancer-Associated Thrombosis and Embolism

GENERAL PRINCIPLES

Definition

Epidemiology

ASSOCIATED DRUGS/THERAPIES

Immunomodulatory Drugs

Tyrosine Kinase Inhibitors

Vascular Endothelial Growth Factor Inhibitors

Epidermal Growth Factor Receptor Inhibitors

Chemotherapy

DIAGNOSIS

Clinical Presentation

Diagnosis

TREATMENT

Initial Treatment of CAT

Long-Term Treatment of CAT

REFERENCES

9 Cardiac Masses

GENERAL PRINCIPLES

CLASSIFICATION OF CARDIAC MASSES

CARDIAC NEOPLASMS

Clinical Presentation

Diagnostic Testing

Classification of Cardiac Neoplasms

REFERENCES

10 Hypertension

GENERAL PRINCIPLES

DIAGNOSIS

Definition

History, Physical Examination, and Diagnostic Testing

EPIDEMIOLOGY

CANCER THERAPIES ASSOCIATED WITH HYPERTENSION

Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

Non–Vascular Endothelial Growth Factor Signaling Pathway Tyrosine Kinase Inhibitors

Proteasome Inhibitors

Platinum-Based Chemotherapeutic Agents

Androgen Axis Inhibitors

Immunosuppressants

MANAGEMENT OF CANCER THERAPY–ASSOCIATED HYPERTENSION

Pretreatment Evaluation

On-Treatment Blood Pressure Surveillance

Selection of Antihypertensive Drugs

REFERENCES

11 Arrhythmias

GENERAL PRINCIPLES

Definition

Classification

RHYTHM DISTURBANCES

ATRIAL FIBRILLATION

Definition

Associated Drugs/Therapies

Diagnosis

Management

SUPRAVENTRICULAR TACHYARRHYTHMIAS (SVTS)

Definition

Associated Drugs/Therapies

Diagnosis

Management

SINUS NODE DYSFUNCTION

Definition

Associated Drugs/Therapies

Diagnosis

Management

ATRIOVENTRICULAR BLOCK

Definition

Associated Drugs/Therapies

Diagnosis

Management

QT PROLONGATION

Definition

Associated Drugs/Therapies

Diagnosis

Management

VENTRICULAR ARRHYTHMIAS

Definition

Associated Drugs/Therapies

Diagnosis

Management

Diagnostic Tests

REFERENCES

12 Intravascular Devices and Thrombotic Complications

PACEMAKER (PM) AND IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD)

GENERAL PRINCIPLES

Indications

Radiation Considerations for Patients With PM or ICD

GUIDELINES/RECOMMENDATIONS FOR PMS AND IRRADIATION

ROLE OF LEADLESS PM

PORTS

GENERAL PRINCIPLES

CONSIDERATIONS

COMPLICATIONS

Early Complications

Delayed Complications

THROMBOTIC COMPLICATIONS: INFERIOR VENA CAVA FILTER (IVCF), PERCUTANEOUS SUCTION THROMBECTOMY SYSTEMS, STENTING

GENERAL PRINCIPLES

CARDIAC COMPLICATIONS

ALTERNATIVE MANAGEMENT

Thrombolytics and Catheter-Directed Thrombolysis

IVC Filter

Percutaneous Suction Thrombectomy Systems

Stenting

REFERENCES

13 Autonomic Dysfunction

GENERAL PRINCIPLES

Definition

Classification

Background and Epidemiology

AntiNeoplastic Chemotherapies

Amyloidosis

Radiation Therapy and Surgery

Paraneoplastic Autonomic Dysfunction

ANATOMY AND PATHOPHYSIOLOGY

Autonomic Nervous System

Mechanisms of Neurotoxicity

AMYLOIDOSIS

Radiation and Surgery

PARANEOPLASTIC SYNDROMES

DIAGNOSIS

Differential Diagnosis for Orthostasis

History

Physical Examination and Bedside Maneuvers

Diagnostic Testing

TREATMENT

PROGNOSIS

REFERENCES

14 Echo Techniques for Cardiac Safety During and After Cancer Treatment

GENERAL PRINCIPLES

The Role of Echocardiography in Surveillance

DEFINITIONS

Cardiotoxicity

HISTORY OF SAFETY MONITORING

Early Modalities for Cardiac Evaluation

The Evolution of Echocardiography

ECHOCARDIOGRAPHIC TECHNIQUES FOR MONITORING

Two-Dimensional Imaging

Doppler

Three-Dimensional Imaging

Myocardial Strain and Early Detection of Left Ventricular Dysfunction

Contrast-Enhancing Agents

ECHOCARDIOGRAPHY SCREENING FOR CARDIOVASCULAR TOXICITY OF CANCER THERAPY

Cancer Treatment–Related Cardiac Dysfunction (CTRCD)

Valvular Heart Disease

Pericardial Disease

Vascular Toxicity

LIMITATIONS OF ECHOCARDIOGRAPHY

REFERENCES

15 Biomarkers as a Tool For Cardiac Safety

GENERAL PRINCIPLES

Definitions

Cardio-Oncology Biomarkers

Investigational Biomarkers

BIOMARKERS IN PRACTICE

Anthracyclines

Trastuzumab

Vascular Endothelial Growth Factor Inhibitors

Proteasome Inhibitors

Immune Checkpoint Inhibitors

Amyloidosis

Integration of Biomarkers into Cardio-Oncology Care

Cardiac Biomarker Profiles

Initial Cardiac Biomarker–Based Workup

Diagnosis and Intervention

CLINICAL VIGNETTES

Case 1: Breast Cancer

Case 2: Immune Checkpoint Inhibitors

CASE 3: ANTHRACYCLINE THERAPY

CASE 4: AMYLOIDOSIS

CASE 5: CANCER SURVIVORSHIP

ADDITIONAL RESOURCES

REFERENCES

16 MRI Techniques to Monitor Cardiac Safety During and After Cancer Treatment

CANCER THERAPY–RELATED CARDIAC DYSFUNCTION

Functional Assessment

Myocardial Strain

Tissue Characterization

Myocardial Edema

Myocardial T1 Mapping

Gadolinium-Based Imaging

INFILTRATIVE CARDIOMYOPATHY/AMYLOIDOSIS

IMMUNE CHECKPOINT INHIBITOR–RELATED MYOCARDITIS

CARDIAC TUMORS

CMR IN RADIATION-INDUCED HEART DISEASE

SUMMARY AND FUTURE DIRECTIONS

REFERENCES

17 Cancer Survivorship: Adverse Outcomes and Other Long-term Cardiovascular Considerations

GENERAL PRINCIPLES

STANDARDS OF SURVIVORSHIP CARE

GENERAL PRINCIPLES

CARDIAC COMPLICATIONS

GENERAL PRINCIPLES

VASCULAR COMPROMISE

STRUCTURAL ABNORMALITIES

Valvular

Pericardial

Conduction Disease

MYOCARDIAL DYSFUNCTION, HEART FAILURE

OTHER MEDICAL COMPLICATIONS

Secondary Malignant Neoplasms

Adverse Hormonal Effects

Reproductive Considerations

Lymphedema

Pain

PSYCHOLOGICAL AND SOCIAL COMPLICATIONS

PSYCHIATRIC ISSUES

COGNITIVE FUNCTION

FATIGUE

Educational Achievement

IMMUNIZATION CONSIDERATIONS

TRANSITIONING TO ADULT-CENTERED CARE

SUMMARY

REFERENCES

18 Hematopoietic Cell Transplantation

OVERVIEW OF HEMATOPOIETIC CELL TRANSPLANTATION

Types of Hematopoietic Cell Transplantation

Indications for Hematopoietic Cell Transplantation

Hematopoietic Cell Transplantation Procedures and Techniques

PRETRANSPLANT CARDIOVASCULAR EVALUATION

Cardiovascular Screening

Cardiovascular Optimization

CARDIOVASCULAR COMPLICATIONS OF HEMATOPOIETIC CELL TRANSPLANTATION

Early Cardiovascular Complications

Late Cardiovascular Complications

Hematopoietic Cell Transplantation Survivorship Considerations

CARDIAC COMPLICATIONS OF CHRONIC GRAFT-VERSUS-HOST DISEASE

REFERENCES

19 Drug-Drug Interactions and the importance of a PharmD

GENERAL PRINCIPLES

Definitions

PHARMACODYNAMIC DRUG INTERACTIONS

RESOURCES

REFERENCES

20 Permissive Cardiotoxicity

GENERAL PRINCIPLES

Definition

PREVENTION

EARLY IDENTIFICATION AND SUBCLINICAL LEFT VENTRICULAR DYSFUNCTION

RISK-BENEFIT ANALYSIS

INDICATIONS TO STOP THERAPY

SELECTED SPECIFIC DRUGS/THERAPIES

Anthracyclines

Human Epidermal Growth Factor Receptor 2 Antagonists

Checkpoint Inhibitors

REFERENCES

21 Multidisciplinary Approach to Cardio-Oncology and the Use of Advanced Practice Provider

MULTIDISCIPLINARY TEAM

Definition

COLLABORATION WITH OTHER DISCIPLINES

CRITICAL ROLE OF ADVANCED PRACTICE PROVIDERS ON THE C-O TEAM

ROLE OF NURSE COORDINATORS FOR THE CARDIO-ONCOLOGY MULTIDISCIPLINARY TEAM

CARDIO-ONCOLOGY RESEARCH: MULTIDISCIPLINARY APPROACH

THE ROLE OF ADMINISTRATIVE SUPPORT IN CARDIO-ONCOLOGY

REFERENCES

22 Cardiac Amyloidosis: General Diagnostic Approach

GENERAL PRINCIPLES

BACKGROUND AND EPIDEMIOLOGY

Epidemiology

CLINICAL EVALUATION

History

Physical Examination

Initial Diagnostic Testing

Establishing the Diagnosis of Cardiac Amyloidosis

REFERENCES

23 Light Chain Amyloidosis: Latest Treatment Strategies

GENERAL PRINCIPLES

STAGING

TREATMENT

Initial Therapy

Autologous Stem Cell Transplantation

Therapy for Relapsed/Refractory Disease

Amyloid Fibril-Targeting Therapy

ASSESSMENT OF TREATMENT RESPONSE

REFERENCES

24 Cardiac Amyloidosis: Latest Treatment Strategies for Transthyretin Amyloidosis

GENERAL PRINCIPLES

BACKGROUND

STAGING AND PROGNOSIS OF TRANSTHYRETIN CARDIAC AMYLOIDOSIS

TRANSTHYRETIN-DIRECTED THERAPY

Transthyretin Stabilizers

Transthyretin Synthesis Inhibitors

MANAGEMENT OF SYMPTOMATIC HEART FAILURE

ADVANCED HEART FAILURE THERAPIES

MANAGEMENT OF ORTHOSTATIC HYPOTENSION

Aggravating Factors

Nonpharmacologic Management

Pharmacologic Management

MANAGEMENT OF RHYTHM DISTURBANCES

REFERENCES

25 Cancer Survivors and Advanced Heart Failure Therapies

GENERAL PRINCIPLES

Definition

Epidemiology

DIAGNOSIS

Clinical Presentation

Diagnostic Testing

TREATMENT

Evaluation for Mechanical Circulatory Support

Pretransplant Considerations

Posttransplant Considerations

OUTCOMES

Summary

REFERENCES

Index

 

▶ Click Here( https://www.medcore.kr )to Homepage

 

---

 

The Washington Manual of Cardio-Oncology